July 16th, 2001

Drug Ads Hyping Anxiety Make Some Uneasy

By Shankar Vedantam
Washington Post

About two years ago, newspaper, magazine and television news stories began
popping up across the country about a little-known malady called social anxiety
disorder. Psychiatrists and patient advocates appeared on television shows and
in articles explaining that the debilitating form of bashfulness was extremely
widespread but easily treatable.

The stories and appearances were part of a campaign, coordinated by a New York
public relations agency, that included pitches to newspapers, radio and TV,
satellite and Internet communications, and testimonials from advocates and doctors
who said social anxiety was America’s third most common mental disorder with
more than 10 million sufferers.

So successful was the campaign that according to a marketing newsletter, media
accounts of social anxiety rose from just 50 stories in 1997 and 1998 to more
than 1 billion references in 1999 alone. And about 96 percent of the stories,
said the report in PR News, "delivered the key message, ‘Paxil is the first
and only FDA-approved medication for the treatment of social anxiety disorder.’
"

The plug for a drug was no accident. Cohn & Wolfe, the public relations
agency coordinating the campaign, did not serve at the pleasure of the doctors
and patient advocates who participated in the education campaign. Instead, the
agency worked at the behest of SmithKline Beecham, the pharmaceutical giant
now known as Glaxo SmithKline, which makes the antidepressant Paxil.

The campaign was supplemented by a multimillion-dollar marketing and advertising
blitz that pitched the drug to doctors, audiences of television shows such as
"Ally McBeal" and readers of magazines such as Rolling Stone. Sales
of Paxil, which had been lagging those of Prozac and Zoloft, jumped, rising
18 percent last year alone.

The education and advertising campaigns have raised concerns that pharmaceutical
companies, traditionally in the business of finding new drugs for existing disorders,
are increasingly in the business of seeking new disorders for existing drugs.
Critics accuse the companies of recruiting patients by teaming up with doctors
and patient advocates—with all the attendant conflicts of agenda and conflicts
of interest.

"Pharmaceutical companies who are marketing psychopharmacological treatments
have gotten into the business of selling psychiatric illness," said Carl
Elliott, a bioethicist at the University of Minnesota, who studies the philosophy
of psychiatry. "The way to sell drugs is to sell psychiatric illness. If
you are Paxil and you are the only manufacturer who has the drug for social
anxiety disorder, it’s in your interest to broaden the category as far as possible
and make the borders as fuzzy as possible."

Blurring the Lines

Blurring the line between normal personality variation and real psychiatric
conditions can trivialize serious mental illness, some experts said.

"Some marketing seems to imply that huge proportions of the population
need pharmaceutical intervention for relatively common problems, and in the
long run, I am concerned that that may undermine the credibility of the concept
of serious mental illness," said Rex Cowdry, medical director of the National
Alliance for the Mentally Ill, a patient advocacy group.

Glaxo SmithKline did not make company officials available for comment, despite
repeated requests. But doctors and advocates associated with the company’s campaign
defended the effort, saying it informed thousands of people who previously did
not know they were suffering from the disorder, spurring many to seek needed
help.

"When I talk to family physicians, I don’t hear them saying I have all
these people who are asking for medicines they don’t need," said Murray
Stein, a psychiatry professor at the University of California in San Diego.
"They say this patient said she had social anxiety and I’ve been treating
her for years and I never thought to ask about it. What could be negative about
that?"

Advocates Hail Attention

Although many of the participants said they served as paid consultants or scientific
investigators for the company, they rejected any notion that they were manipulated
by the pharmaceutical industry. Most said they had spent years toiling on social
anxiety disorder and were delighted when SmithKline offered a way to get their
message out.

"I know there’s lots of concern about, ‘Are we medicalizing normative
things and is the pharmaceutical industry trying to put SSRIs in the water,’
" Stein said, referring to the class of drugs known as selective serotonin
reuptake inhibitors, which includes Paxil. "The people I see talking about
that have not seen these patients."

Patients with social anxiety disorder aren’t the shy people who hang out at
the edges of parties. Those truly suffering from the condition are profoundly
debilitated, refusing promotions or taking jobs as night guards because they
can’t stand to be around people. Some cannot open the door to a handyman because
that would mean conversation.

"Would somebody who is not having problems take a medicine that is costly
and has side effects?" Stein asked. "I don’t think too many people
would do that. The idea that this is cosmetic psychopharmacology I find offensive."

The advocacy organizations that participated in the campaign—the American
Psychiatric Association, the Anxiety Disorders Association of America and a
Long Island-based group called Freedom From Fear—said that the only way for
nonprofit groups to get out a potent public health message is to team up with
a pharmaceutical company with deep pockets. Moreover, the groups demanded and
received full control over the editorial content of the education campaign,
said John Blamthin, an APA spokesman.

"We have never, ever promoted any drug," said Jerilyn Ross, the founder
of the Anxiety Disorders Association of America. "If you look at our materials
and on our Web site, we have never mentioned a drug." Ross said that she
even got into "fights" with SmithKline because she frequently told
the company’s marketers, " ‘We can’t do this, we can’t do that.’ "

But if the experts did not want to be boosters for Paxil, the arrangement with
the public relations firm—and the marketing campaign for Paxil, which offered
journalists interviews with some of the same experts—made that confusing.
Cohn & Wolfe emphasized in its calls to the media that it spoke on behalf
of doctors and nonprofits—not the pharmaceutical company that was paying
its bills.

The Cohn & Wolfe Web site, however, made no secret of the fact that it
is in the business of marketing, not public health: On a previous campaign to
promote coverage about the 10th anniversary of Prozac’s launch in Britain, the
agency said it successfully helped drug maker Eli Lilly spin coverage. The strategy?
Offer journalists interviews with "independent Key Opinion Leaders"
—doctors, advocacy groups and patients with "suitable debate."

Cohn & Wolfe declined to talk about its role in the Paxil campaign, calling
the information "proprietary and confidential."

Business of Educating

Marcia Angell, a former editor of the New England Journal of Medicine, said
that pharmaceutical companies could not be expected to act solely in the interest
of public health: "They are no more in the business of educating the public
than a beer company is in the business of educating people about alcoholism."

The expensive ad and education campaign paid off in the crowded antidepressant
market: Glaxo SmithKline’s 2000 annual report told shareholders the drug "became
number one in the U.S. selective serotonin reuptake inhibitor market for new
retail prescriptions in 2000."

Barry Brand, Paxil’s product director, told the journal Advertising Age, "Every
marketer’s dream is to find an unidentified or unknown market and develop it.
That’s what we were able to do with social anxiety disorder."

Several experts, including some who treat social anxiety disorder, worried
whether such marketing was in the public’s best interest.

"When the pharmaceutical companies focus on broadening the market, you
miss out on the fact that there is a proportion of people for whom mental illnesses
are truly disabling," said Cowdry, who formerly headed the National Institute
of Mental Health. "I have the same reaction when I hear that one in three
Americans have a mental illness. The problem with that kind of data is that
it undermines credibility—it doesn’t pass the laugh test."

Sizing Up the Problem

Two experts who were assembled by the American Psychiatric Association to write
the definition of social anxiety disorder for the psychiatrist’s manual said
they admired the campaign for alerting patients suffering in silence. Still,
they had concerns.

"I don’t think the ads make the distinction between social anxiety and
shyness," said Edna Foa, a professor of psychology at the University of
Pennsylvania who served on the APA committee. "One gets the impression
from the ads that if you are shy and you have some difficulties and you want
to be outgoing, then take Paxil. You are promoting medication when it is unnecessary."

There were other instances where the social anxiety marketing campaign diverted
from the message of medical experts—including experts who were part of the
education campaign—or quoted the experts selectively.

The campaign said that more than 10 million Americans suffered from social
anxiety disorder, making it the most common mental disorder after depression
and alcoholism—and that 13 percent of Americans are affected by social anxiety
disorder. But the National Institute of Mental Health says only about 3.7 percent
of the U.S. population has social anxiety disorder. The American Psychiatric
Association says rates vary between 3 percent and 13 percent. Stein of UCSD
said he preferred the 3 percent to 4 percent estimate.

Although Paxil has been specifically approved by the Food and Drug Administration
for the disorder, many psychiatrists said there is probably little difference
between Paxil and similar medicines such as Prozac or Zoloft in treating social
anxiety. There are also other types of drugs available for treating other forms
of anxiety.

And although the campaign mentioned a psychological therapy called cognitive
behavior therapy, it did not stress that the therapy is as effective as medication,
has no side effects, such as sexual problems and fatigue, and does not require
patients to stay on treatment indefinitely.

"In my opinion, social anxiety is not a chemical problem with the brain,"
said Jonathan Abramowitz, a psychologist at the Mayo Clinic in Rochester, Minn.,
who worked on the psychiatrist’s manual. "I see it as a problem with normal
thinking and behaviors that have gone awry."

Cognitive behavior therapy, he said, takes 14 weeks: "It’s like learning
to ride a bike. You are practicing these skills over and over. No one can take
them away from you the rest of your life. The long-term benefits of cognitive
therapy is better than medicine because with medicine, when you stop, the symptoms
come back."

Comments

  1. Posted by Meghan on December 9th, 2005

    What was the first prescription drug commercial to advertise on american television? 

Add your own Comment

(optional)